Search research articles
Contact Us
Filters
Showing results (81-90 of 133) with videos related to
Page
of 14
Sort By:
Frontiers in Cardiovascular Medicine
|
October 3, 2022
Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, et al.
European Journal of Internal Medicine
|
March 12, 2024
Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score
Francesco Santoro, Ivan J Núñez-Gil, María C Viana-Llamas, et al.
Respiratory Research
|
February 8, 2024
Symptomatic post COVID patients have impaired alveolar capillary membrane function and high VE/VCO<sub>2</sub>
Piergiuseppe Agostoni, Massimo Mapelli, Elisabetta Salvioni, et al.
Heart (British Cardiac Society)
|
April 16, 2025
Integrating pulmonary function testing with cardiopulmonary exercise testing for enhanced stratification in hypertrophic cardiomyopathy
Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, et al.
ESC Heart Failure
|
March 17, 2026
Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study
Giuseppe Dattilo, Roberto Licordari, Egidio Imbalzano, et al.
International Journal of Molecular Sciences
|
August 28, 2025
Short-term effects of DAPAgliflozin on Lung fUNction, sleep apneas, and circulatinG surfactant protein B in Heart Failure with reduced ejection fraction (DAPA-LUNG-HF)
Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, et al.
Frontiers in Cardiovascular Medicine
|
April 1, 2025
Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, et al.
European Journal of Preventive Cardiology
|
August 12, 2025
Cardiopulmonary exercise testing in hypertrophic cardiomyopathy: the role of reduced O2 pulse and chronotropic incompetence in myocardial adaptation
Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, et al.
European Journal of Preventive Cardiology
|
May 17, 2022
Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set
Damiano Magrì, Massimo Piepoli, Giovanna Gallo, et al.
Journal of the American Heart Association
|
April 9, 2026
RoMa: A Cardiopulmonary Exercise Testing Based Risk Tool in Hypertrophic Cardiomyopathy
Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 133) with videos related to
Sort By:
Page
of 14
Frontiers in Cardiovascular Medicine
|
October 3, 2022
Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, et al.
European Journal of Internal Medicine
|
March 12, 2024
Risk prediction of major cardiac adverse events and all-cause death following covid-19 hospitalization at one year follow-up: The HOPE-2 score
Francesco Santoro, Ivan J Núñez-Gil, María C Viana-Llamas, et al.
Respiratory Research
|
February 8, 2024
Symptomatic post COVID patients have impaired alveolar capillary membrane function and high VE/VCO<sub>2</sub>
Piergiuseppe Agostoni, Massimo Mapelli, Elisabetta Salvioni, et al.
Heart (British Cardiac Society)
|
April 16, 2025
Integrating pulmonary function testing with cardiopulmonary exercise testing for enhanced stratification in hypertrophic cardiomyopathy
Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, et al.
ESC Heart Failure
|
March 17, 2026
Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study
Giuseppe Dattilo, Roberto Licordari, Egidio Imbalzano, et al.
International Journal of Molecular Sciences
|
August 28, 2025
Short-term effects of DAPAgliflozin on Lung fUNction, sleep apneas, and circulatinG surfactant protein B in Heart Failure with reduced ejection fraction (DAPA-LUNG-HF)
Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, et al.
Frontiers in Cardiovascular Medicine
|
April 1, 2025
Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, et al.
European Journal of Preventive Cardiology
|
August 12, 2025
Cardiopulmonary exercise testing in hypertrophic cardiomyopathy: the role of reduced O2 pulse and chronotropic incompetence in myocardial adaptation
Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, et al.
European Journal of Preventive Cardiology
|
May 17, 2022
Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set
Damiano Magrì, Massimo Piepoli, Giovanna Gallo, et al.
Journal of the American Heart Association
|
April 9, 2026
RoMa: A Cardiopulmonary Exercise Testing Based Risk Tool in Hypertrophic Cardiomyopathy
Robin Willixhofer, Massimo Mapelli, Nikita Baracchini, et al.
Page
of 14